Company / R&D Expense
Vaxcyte, Inc. R&D Expense History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$794.3M
FY2025
5-year range
$78.4M / $794.3M
FY2021-FY2025
Trend
+66.6%
vs FY2024
Sector context
#24 of 210
Health Care
What the data says
Vaxcyte, Inc.'s r&d expense of $794M is higher than 89% of companies in the Health Care sector (FY2025). R&D Expense has increased for 7 consecutive years, from $30M in FY2018 to $794M in FY2025.
Based on SEC 10-K filings.
$794M in FY2025 with a 5-year CAGR of +60.9%. Top quartile in the Health Care sector.
Improved from $332M to $794M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +67.4%
- 5-Year CAGR
- +60.9%
- 10-Year CAGR
- -
Sector benchmark
Top 11% in Health CareTop 11% of 210This company $794.3M Sector average $644.1M
▼
+23.3% above sector average
Key checks
Key Insights
- Vaxcyte, Inc.'s r&d expense has grown for 7 consecutive years.
- 5-year CAGR of +60.9%, indicating consistent growth.
- In FY2025, r&d expense increased 66.6% year-over-year.
- Ranks #24 out of 210 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 2.94 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $794.3M | +66.6% |
| FY2024 | $476.6M | +43.4% |
| FY2023 | $332.3M | +96.1% |
| FY2022 | $169.5M | +116.1% |
| FY2021 | $78.4M | +6.6% |
| FY2020 | $73.6M | +61.3% |
| FY2019 | $45.6M | +51.3% |
| FY2018 | $30.1M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026